PubRank

Julian D Gillmore

Author PubWeight™ 57.36‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007 4.54
2 Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002 4.47
3 Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003 2.74
4 A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013 2.38
5 Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circ Res 2013 2.26
6 Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010 2.20
7 Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med 2015 1.84
8 Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010 1.81
9 Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012 1.80
10 Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2006 1.54
11 Inflammatory bowel disease and systemic AA amyloidosis. Dig Dis Sci 2013 1.43
12 Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008 1.38
13 Systemic amyloidosis and the gastrointestinal tract. Nat Rev Gastroenterol Hepatol 2009 1.34
14 Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. N Engl J Med 2012 1.26
15 Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat 2014 1.23
16 Outcome in renal Al amyloidosis after chemotherapy. J Clin Oncol 2011 1.21
17 Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc 2013 1.20
18 AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood 2008 1.20
19 Perspectives in treatment of AL amyloidosis. Br J Haematol 2007 1.17
20 Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol 2006 1.13
21 Systemic amyloidosis in England: an epidemiological study. Br J Haematol 2013 1.08
22 Decreasing incidence of AA amyloidosis in Spain. Eur J Clin Invest 2013 1.08
23 Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. Am J Pathol 2011 1.04
24 Structure, folding dynamics, and amyloidogenesis of D76N β2-microglobulin: roles of shear flow, hydrophobic surfaces, and α-crystallin. J Biol Chem 2013 1.04
25 The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. Am Heart J 2012 1.03
26 V122I transthyretin variant in elderly black Americans. N Engl J Med 2015 0.99
27 AA amyloidosis complicating the hereditary periodic fever syndromes. Arthritis Rheum 2013 0.94
28 The importance of complete screening for amyloid fibril type and systemic disease in patients with amyloidosis in the respiratory tract. Sarcoidosis Vasc Diffuse Lung Dis 2002 0.91
29 AA-amyloidosis caused by visceral leishmaniasis in a human immunodeficiency virus-infected patient. Am J Trop Med Hyg 2009 0.89
30 Guidelines on the management of AL amyloidosis. Br J Haematol 2014 0.87
31 Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J 2011 0.87
32 Clinical characteristics in subjects with NLRP3 V198M diagnosed at a single UK center and a review of the literature. Arthritis Res Ther 2013 0.85
33 Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis. Proc Natl Acad Sci U S A 2014 0.84
34 Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation. Nat Clin Pract Cardiovasc Med 2008 0.82
35 Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens. Br J Haematol 2014 0.82
36 Novel gelsolin variant as the cause of nephrotic syndrome and renal amyloidosis in a large kindred. Amyloid 2014 0.81
37 An unusual cause of carpal tunnel syndrome. Pract Neurol 2011 0.79
38 Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis. Haematologica 2011 0.79
39 Renal amyloidosis. Br J Hosp Med (Lond) 2010 0.78
40 Clinical characteristics and SAP scintigraphic findings in 10 patients with AGel amyloidosis. Amyloid 2014 0.78
41 Clinical profile and treatment outcomes of immunoglobulin D associated AL amyloidosis. Br J Haematol 2013 0.77
42 High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2008 0.76
43 A prospective study of nutritional status in immunoglobulin light chain amyloidosis. Haematologica 2012 0.76
44 Systemic diseases: from amyloidosis to cryoglobulinemia. Clin J Am Soc Nephrol 2010 0.75
45 Hereditary fibrinogen A alpha-chain amyloidosis: clinical phenotype and role of liver transplantation. Blood 2010 0.75
46 CMR-Verified Regression of Cardiac AL Amyloid After Chemotherapy. JACC Cardiovasc Imaging 2017 0.75
47 A white man with a very African form of hereditary amyloid cardiomyopathy. Br J Hosp Med (Lond) 2014 0.75
48 A novel transthyretin variant p.H110D (H90D) as a cause of familial amyloid polyneuropathy in a large Irish kindred. Amyloid 2014 0.75
49 Retinal microangiopathy as an initial manifestation of familial amyloid cardiomyopathy associated with transthyretin e89k mutation. Retin Cases Brief Rep 2013 0.75
50 Should Histologic Determination of Amyloid Load Determine Management Decisions in Light-Chain Amyloidosis? J Am Coll Cardiol 2016 0.75